Browse > Article
http://dx.doi.org/10.13103/JFHS.2022.37.3.198

The Effects of Ecklonia stolonifera Extracts on Improvement of Hepatic Function: a Double-Blind, Randomized, Placebo-Controlled Clinical Study  

Kim, Junghee (R&D Center, Naturalway Co. Ltd.)
Kim, Eun Jin (R&D Center, Naturalway Co. Ltd.)
Kang, Dahye (R&D Center, Naturalway Co. Ltd.)
Kim, Hyung-Bin (R&D Center, Naturalway Co. Ltd.)
Jang, Jae Young (Department of Internal Medicine, Institute for Digestive Research, Digestive Disease Center, Soonchunhyang University College of Medicine)
Om, Ae-Son (Department of Food and Nutrition, College of Human Ecology, Hanyang University)
Kim, Jongwook (R&D Center, Naturalway Co. Ltd.)
Publication Information
Journal of Food Hygiene and Safety / v.37, no.3, 2022 , pp. 198-205 More about this Journal
Abstract
Hepatic diseases are divided into two types: alcoholic and non-alcoholic. Non-alcoholic liver injury finally induces fatty liver and damages liver function. Many studies have demonstrated that Ecklonia stolonifera has antioxidative, anti-inflammatory, and hepatoprotective activities. We conducted a 12-week double-blind, placebo-controlled, randomized trial to examine the efficacy of E. stolonifera extracts (ESE) on biochemical markers of hepatic function. Sixty-five subjects with mild or moderate liver injuries were randomly allocated to receive either 420 mg/d of ESE or a placebo for 12 weeks. Fifty-five participants completed the trial. No significant adverse events were observed among the subjects during the study. The primary end points were changes in plasma levels of aspartate transaminase (AST), alanine transaminase (ALT), and γ-glutamyltransferase (γ-GT). The secondary end points were changes in lipid profile levels, including total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL), and low-density lipoprotein cholesterol (LDL). Compared with the baseline, AST and ALT levels decreased significantly in the ESE group compared to those in the placebo group (P<0.001). In addition, γ-GT levels in the ESE group were significantly lower than those in the placebo group (P=0.016). There were no differences in the TC, TG, HDL, and LDL levels between groups. In conclusion, ESE consumption for 12 weeks improved liver parameters in subjects with liver injury. Regular consumption of ESE could maintain liver health in individuals at risk of hepatic damage.
Keywords
Ecklonia stolonifera extract; Liver injury; Hepatic function; Health functional food;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Lee, H.J., White paper on liver diseases in Korea. Korean Association for the Study of the Liver, 21 (2021).
2 National Institute of Food and Drug Safety Evaluation, Guides for safety and efficacy evaluation of health functional food(May help to liver health), (2020).
3 Kim, H.K., Suh, C.J., Yoon, H.J., Hwang, Y.H., Lee, K.Y., Park, H.Y., Kim, K.H., Kang, M.H., Association between non-alcoholic fatty liver and metabolic diseases. J. Kor. Endocrine. Soc., 17, 526-534 (2002).
4 Eslam, M., Sanyal, A.J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D.E., Brunt, E., Bugianesi, E., Yki-Jarvinen, H., MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 158, 1999-2014 (2020).   DOI
5 Lee, H.J., Non-alcoholic fatty liver disease clinical practice guidelines. Korean Association for the Study of the Liver, 5-14 (2021).
6 Ministry of Food and Drug Safety, 2022.02.11., Available from: https://www.foodsafetykorea.go.kr/main.do
7 Byun, J.H., Kim, J., Choung, S.Y., Hepaprotective Effect of Standardized Ecklonia stolonifera Formulation on CCl4-Induced Liver Injury in Sprague-Dawley Rats. Biomol. Ther. (Seoul), 26, 218-223 (2018).   DOI
8 Lee, M.S., Shin, T., Utsuki, T., Choi, J.S., Byun, D.S., Kim, H.R., Isolation and identification of phlorotannins from Ecklonia stolonifera with antioxidant and hepatoprotective properties in tacrine-treated HepG2 cells. J. Agric. Food Chem., 60, 5340-5349 (2012).   DOI
9 Browning, J.D., Horton, J.D., Molecular mediators of hepatic steatosis and liver injury. J. Clin. invest., 114, 147-152 (2004).   DOI
10 You, M., Crabb, D.W., Recent advances in alcoholic liver disease II. minireview: molecular mechanisms of alcoholic fatty liver. Am. J. Physiol. Gastrointest. Liver Physiol., 287, G1-G6 (2004).   DOI
11 Jin, H., Lee, K., Chei, S., Oh, H.J., Lee, K.P., Lee, B.Y., Ecklonia stolonifera extract suppresses lipid accumulation by promoting lipolysis and adipose browning in high-fat diet-induced obese male mice. Cells, 9, 871 (2020).   DOI
12 Lee, M.S., Kim, J.I., Utsuki, T., Park, N.G., Kim, H.R., Cytoprotective effects of phlorofucofuroeckol A isolated from Ecklonia stolonifera against tacrine-treated HepG2 cells. Fitoterapia, 83, 1060-1067 (2012).   DOI
13 Han, X., Kim, W.H., Choi, S.I., Men, X., Lee, S.j., Jin, H., Oh, H.J., Kang, D., Kim, H., Lee, B.Y., Lee, O.H., Antioxidant and anti-cholesterol activities of standardized Ecklonia Stolonifera extract. J. Food Hyg. Saf., 36, 353-362 (2021).   DOI
14 Yoon, J.S., Kasin Yadunandam, A., Kim, S.J., Woo, H.C., Kim, H.R., Kim, G.D., Dieckol, isolated from Ecklonia stolonifera, induces apoptosis in human hepatocellular carcinoma Hep3B cells. J. Nat. Med., 67, 519-527 (2013).   DOI
15 Bang, C.Y., Byun, J.H., Choi, H.K., Choi, J.S., Choung, S.Y., Protective effects of Ecklonia stolonifera extract on ethanol-induced fatty liver in rats. Biomol. Ther. (Seoul), 24, 650-658 (2016).   DOI
16 Wang, N., Kong, R., Luo, H., Xu, X., Lu, J., Peroxisome proliferator-activated receptors associated with nonalcoholic fatty liver disease. PPAR Res., 6561701 (2017).   DOI
17 Kang, H.S., Chung, H.Y., Kim, J.Y., Son, B.W., Jung, H.A., Choi, J.S., Inhibitory phlorotannins from the edible brown alga Ecklonia stolonifera on total reactive oxygen species (ROS) generation. Arch. Pharm. Res., 27, 194-198 (2004).   DOI
18 Katagiri, T., Sunagawa, Y., Maekawa, T., Funamoto, M., Shimizu, S., Shimizu, K., Katanasaka, Y., Komiyama, M., Hawke, P., Hara, H., Mori, K., Hasegawa, K., Morimoto, T., Ecklonia stolonifera Okamura extract suppresses myocardial infarction-induced left ventricular systolic dysfunction by inhibiting p300-HAT activity. Nutrients, 14, 580 (2022).   DOI
19 Han, B., Kim, S.M., Nam, G.E., Kim, S.H., Park, S.J., Park, Y.K., Baik, H.W., A randomized, double-Blind, placebo-controlled, multi-centered clinical study to evaluate the efficacy and safety of Artemisia annua L. extract for improvement of liver function. Clin. Nutr. Res., 9, 258 (2020).   DOI
20 Horton, J.D., Goldstein, J.L., Brown, M.S., SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. invest., 109, 1125-1131 (2002).   DOI
21 Goo, H.R., Choi, J.S., Na, D.H., Quantitative determination of major phlorotannins in Ecklonia stolonifera. Arch. Pharm. Res., 33, 539-544 (2010).   DOI
22 Seo, Y., Lee, S.H., Hwang, H.S., Choe, S.Y., Effects of nonalcoholic fatty liver in rats by Acer tagmentosum Maxim. Extract. Korean J. Food & Nutr., 29, 307-312 (2016).   DOI
23 Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M., Sanyal, A.J., Mechanisms of NAFLD development and therapeutic strategies. Nat. Med., 24, 908-922 (2018).   DOI
24 Liss, K.H., Finck, B.N., PPARs and nonalcoholic fatty liver disease. Biochimie, 136, 65-74 (2017).   DOI
25 Lee, H.J., Non-alcoholic fatty liver disease clinical practice guidelines. Korean Association for the Study of the Liver, 40-45 (2021).
26 Choi, J.S., Han, Y.R., Byeon, J.S., Choung, S.Y., Sohn, H.S., Jung, H.A., Protective effect of fucosterol isolated from the edible brown algae, Ecklonia stolonifera and Eisenia bicyclis, on tert-butyl hydroperoxide- and tacrine-induced HepG2 cell injury. J. Pharm. Pharmacol., 67, 1170-1178 (2015).   DOI
27 Yu, S., Kim, W., Health beneficial effects of brown algae Ecklonia stolonifera in liver. Food Sci. Ind., 51, 334-342 (2018).   DOI